Related Experiment Video
Updated: Jun 11, 2026
04:48
Control of Eating Behavior Using a Novel Feedback System
Published on: May 8, 2018
Comparing Automated Lyumjev® Delivery with Carbohydrate Counting, Qualitative Meal-Size Estimation, and Fully
Carolyne Schumacher1, Michael A Tsoukas2,3, Laurent Legault4
1Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada.
Diabetes Technology & Therapeutics
|June 10, 2026
Summary
A new automated insulin delivery (AID) system using Lyumjev insulin simplified mealtime insulin dosing for people with type 1 diabetes. This innovation reduced the need for carbohydrate counting without negatively impacting glucose control.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Medical Devices
Background:
- Carbohydrate counting for prandial insulin dosing presents a significant challenge for individuals with type 1 diabetes (T1D).
- Automated insulin delivery (AID) systems aim to improve glucose management in T1D.
- Ultrarapid lispro insulin (Lyumjev) offers a faster-acting insulin option.
Purpose of the Study:
- To evaluate a novel AID system that replaces carbohydrate counting with qualitative meal-size estimation and meal detection.
- To assess the efficacy of this AID system in adults with T1D.
Main Methods:
- A randomized crossover pilot trial was conducted involving adults with T1D.
- Three AID strategies were compared: AID with carbohydrate counting (AID-count), AID with qualitative meal-size estimation (AID-estimate), and AID with meal detection (AID-fully).
- The study duration was 3 weeks per intervention.
Main Results:
- Twelve participants completed the study.
- No clinically significant differences (greater than 5%) in time in range were observed between AID-estimate or AID-fully compared to AID-count.
- Hypoglycemia and hyperglycemia levels were comparable across all interventions, with no severe adverse events reported.
Conclusions:
- The AID system utilizing Lyumjev effectively simplified or eliminated the need for carbohydrate counting.
- Glucose control was maintained within acceptable limits, showing no degradation greater than 5% compared to traditional carbohydrate counting.
- Larger studies are recommended to further validate these findings.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
00:56One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance
Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
01:18Two-Compartment Open Model: IV Bolus Administration
The two-compartment model for intravenous (IV) bolus administration illustrates drug distribution in the body, subdividing it into central and peripheral compartments. This model operates on the concept of two-compartment kinetics. The drug's plasma concentration shows a bi-exponential decline following IV bolus administration, signaling the presence of two disposition processes: distribution and elimination.
The disparity between drug input and the sum of drug transfer rates between...
The disparity between drug input and the sum of drug transfer rates between...